D.A. Davidson & CO. Acquires 1,529 Shares of Organon & Co. (NYSE:OGN)

D.A. Davidson & CO. raised its stake in shares of Organon & Co. (NYSE:OGN) by 1.3% in the third quarter, HoldingsChannel reports. The institutional investor owned 122,147 shares of the company’s stock after acquiring an additional 1,529 shares during the period. D.A. Davidson & CO.’s holdings in Organon & Co. were worth $2,337,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. LSV Asset Management grew its stake in Organon & Co. by 47.3% during the second quarter. LSV Asset Management now owns 6,610,768 shares of the company’s stock valued at $136,843,000 after acquiring an additional 2,121,940 shares in the last quarter. AQR Capital Management LLC boosted its holdings in shares of Organon & Co. by 39.8% during the 2nd quarter. AQR Capital Management LLC now owns 3,473,655 shares of the company’s stock valued at $71,905,000 after purchasing an additional 988,336 shares during the last quarter. Deprince Race & Zollo Inc. grew its position in shares of Organon & Co. by 6.8% during the second quarter. Deprince Race & Zollo Inc. now owns 3,421,703 shares of the company’s stock valued at $70,829,000 after purchasing an additional 216,907 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Organon & Co. by 35.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 3,323,051 shares of the company’s stock valued at $63,570,000 after purchasing an additional 875,128 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Organon & Co. by 23.8% in the second quarter. Dimensional Fund Advisors LP now owns 2,407,915 shares of the company’s stock worth $49,843,000 after purchasing an additional 463,216 shares during the last quarter. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Down 0.7 %

Shares of NYSE:OGN opened at $15.87 on Friday. The company has a market cap of $4.09 billion, a price-to-earnings ratio of 3.15, a PEG ratio of 0.75 and a beta of 0.84. Organon & Co. has a 12 month low of $10.84 and a 12 month high of $23.10. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The company has a 50-day moving average price of $17.26 and a 200 day moving average price of $19.65.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings data on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). The company had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The company’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter last year, the company earned $0.78 earnings per share. As a group, equities research analysts predict that Organon & Co. will post 3.89 earnings per share for the current year.

Organon & Co. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Tuesday, November 12th will be given a $0.28 dividend. The ex-dividend date is Tuesday, November 12th. This represents a $1.12 dividend on an annualized basis and a yield of 7.06%. Organon & Co.’s dividend payout ratio is presently 22.22%.

Analysts Set New Price Targets

A number of equities analysts recently commented on OGN shares. Evercore ISI raised Organon & Co. to a “strong-buy” rating in a research note on Wednesday, September 18th. JPMorgan Chase & Co. downgraded Organon & Co. from a “neutral” rating to an “underweight” rating and increased their target price for the company from $18.00 to $20.00 in a research report on Friday, September 6th.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.